- Home
- MEIP vs IPA Comparison
MEIP vs IPA Comparison
Compare MEIP & IPA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MEIP
- IPA
- Stock Information
- Founded
- MEIP 2000
- IPA 1983
- Country
- MEIP United States
- IPA Canada
- Employees
- MEIP 28
- IPA N/A
- Industry
- MEIP Biotechnology: Pharmaceutical Preparations
- IPA Biotechnology: Pharmaceutical Preparations
- Sector
- MEIP Health Care
- IPA Health Care
- Exchange
- MEIP Nasdaq
- IPA Nasdaq
- Market Cap
- MEIP 17.3M
- IPA 19.3M
- IPO Year
- MEIP 2003
- IPA 2017
- Fundamental
- Price
- MEIP $2.60
- IPA $0.39
- Analyst Decision
- MEIP Hold
- IPA Strong Buy
- Analyst Count
- MEIP 2
- IPA 2
- Target Price
- MEIP $7.00
- IPA $5.00
- AVG Volume (30 Days)
- MEIP 7.5K
- IPA 1.3M
- Earning Date
- MEIP 02-12-2025
- IPA 03-13-2025
- Dividend Yield
- MEIP N/A
- IPA N/A
- EPS Growth
- MEIP N/A
- IPA N/A
- EPS
- MEIP N/A
- IPA N/A
- Revenue
- MEIP N/A
- IPA $17,272,336.00
- Revenue This Year
- MEIP N/A
- IPA $1.88
- Revenue Next Year
- MEIP N/A
- IPA $9.90
- P/E Ratio
- MEIP N/A
- IPA N/A
- Revenue Growth
- MEIP 33.76
- IPA 6.36
- 52 Week Low
- MEIP $2.30
- IPA $0.33
- 52 Week High
- MEIP $4.42
- IPA $2.43
- Technical
- Relative Strength Index (RSI)
- MEIP 37.79
- IPA 36.66
- Support Level
- MEIP $2.55
- IPA $0.43
- Resistance Level
- MEIP $2.79
- IPA $0.53
- Average True Range (ATR)
- MEIP 0.14
- IPA 0.04
- MACD
- MEIP -0.02
- IPA -0.01
- Stochastic Oscillator
- MEIP 14.71
- IPA 8.42
About MEIP MEI Pharma Inc.
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.
About IPA ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series proprietary and patented technologies. The company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges.